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ABSTRACT
To date, ocular antibody therapies for the treatment of retinal diseases rely on injection of the drug into
the vitreous chamber of the eye. Given the burden for patients undergoing this procedure, less frequent
dosing through the use of long-acting delivery (LAD) technologies is highly desirable. These technologies
usually require a highly concentrated formulation and the antibody must be stable against extended
exposure to physiological conditions. Here we have increased the potential of a therapeutic antibody
antigen-binding fragment (Fab) for LAD by using protein engineering to enhance the chemical and
physical stability of the molecule. Structure-guided amino acid substitutions in a negatively charged
complementarity determining region (CDR-L1) of an anti-factor D (AFD) Fab resulted in increased chemical
stability and solubility. A variant of AFD (AFD.v8), which combines light chain substitutions (VL-D28S:D30E:
D31S) with a substitution (VH-D61E) to stabilize a heavy chain isomerization site, retained complement
factor D binding and inhibition potency and has properties suitable for LAD. This variant was amenable to
high protein concentration (>250 mg/mL), low ionic strength formulation suitable for intravitreal injection.
AFD.v8 had acceptable pharmacokinetic (PK) properties upon intravitreal injection in rabbits, and improved
stability under both formulation and physiological conditions. Simulations of expected human PK behavior
indicated greater exposure with a 25-mg dose enabled by the increased solubility of AFD.v8.
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Introduction
Age-related macular degeneration (AMD) is a progressive
chronic disease of the central retina with signiﬁcant consequen-
ces for visual acuity.1 Advanced forms of the disease include
neovascular AMD and geographic atrophy (GA). Neovascular
AMD is a leading cause of blindness in the Western world. It is
characterized by excessive growth of blood vessels from the cho-
roid behind the retina, and can cause severe visual impairment.
Visual acuity for patients afﬂicted with neovascular AMD is
often improved by treatment with anti–vascular endothelial
growth factor (VEGF) agents such as Lucentis (ranibizu-
mab).2,3 GA is characterized by a progressive loss of photorecep-
tors and retinal pigment epithelial cells, leading to signiﬁcant
visual function impairment and eventual blindness. Even
though GA affects more than 5 million people worldwide,4 there
are currently no approved or effective treatment options for GA.
Although the molecular mechanism leading to GA is not well
understood, studies suggest a link to polymorphisms in genes of
the alternative complement pathway.5 Complement factor D
(CFD),6 a serine protease, catalyzes the cleavage and activation
of factor B, which is a key step in the alternative complement
cascade. It is thus an attractive target for intervention in GA.7
Lampalizumab is a humanized anti–factor D antigen-binding
fragment (AFD) that binds to an exosite on CFD8 and potently
inhibits its activity. Lampalizumab has shown efﬁcacy in the
treatment of GA through monthly 10-mg intravitreal dosing9
and has been advanced to pivotal clinical trials.
Monthly intravitreal drug administration may be burden-
some to some patients, and less frequent dosing would be desir-
able. An increase in the amount dosed could result in improved
treatment interval; however, the limited solubility of AFD at
low ionic strength poses challenges for ocular formulations.
Solubility can be increased with higher ionic strength, but
hypertonic formulations are associated with an increased risk
for retinal edema and detachment.10 Additional challenges
include the small (»100 mL) maximum volume acceptable for
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intravitreal injections, and the ocular clearance rate of antibod-
ies (t1/2 D 9.8 days for bevacizumab26) and antibody Fabs
(t1/2 D 5.9 days for lampalizumab,11,12 7.213–8.614 days for rani-
bizumab) relative to the desired treatment interval.
Sustained-release formulations or engineering of proteins to
extend their half-life could facilitate an extended dosing inter-
val for ocular therapeutics.15 Both approaches for antibody
treatment of back-of-the-eye disorders may require highly con-
centrated formulations and high antibody stability under physi-
ological conditions. Here, we describe the improved solubility
and physical and chemical stability of AFD obtained through
amino acid changes in the complementarity-determining
region (CDR), creating a potential therapeutic that is amenable
to long-acting delivery.
Results
Protein engineering of AFD
The CDR-L1 of AFD (24I-T-S-T-D-I-D-D-D-M-N34) provides
a critical contact for the binding of CFD.8 Asp-30 and Asp-32,
together with Asp-92 from CDR-L3, form an ionic interaction
with Lys-223 of CFD (Figure 1A). Asp-30 is part of a “DD”
motif and undergoes rapid isomerization to the cyclic interme-
diate form that is stable and elutes as a basic peak upon ion-
exchange chromatography.16,17 This basic species showed a
modest decrease, about 2-fold, in CFD-binding afﬁnity
(Supplemental Figure 1). Examination of the structure of the
complex formed between CFD and AFD suggested that
replacement of Asp-30 with less isomerization-prone Glu
might preserve binding. AFD has a high afﬁnity for CFD, as
indicated by KD »10 pM, which is the limit that can be deter-
mined with surface plasmon resonance (SPR) technology.
Thus, variants with KD 10 pM are considered equivalent to
AFD. Within this constraint, the D30E mutant (variant AFD.
v2) retained high afﬁnity for CFD (Table 1).
AFD showed reduced solubility at pH 6 and low ionic
strength (Figure 2), which was reversed through the addition of
salt. Results of molecular docking simulations (Figure 3A) sug-
gested that basic and acidic patches on AFD interact to stitch
together Fabs in repeating units that support extended struc-
tures. We tested whether the acidic CDR-L1 was involved in
these structures by replacing negatively charged residues in this
region with Ser. Aspartic acid residues 28 and 31 in CDR-L1
are not in direct contact with CFD and individual substitution
of these residues with Ser (variants AFD.v1 and AFD.v3,
respectively) did not have any apparent effect on afﬁnity for
CFD (Table 1). In contrast, replacement of Asp32 with Ser
(variant AFD.v4) resulted in a signiﬁcant loss in CFD binding.
Binding loss also occurred when this substitution was com-
bined with the D28S and D31S mutants (variant AFD.v5). The
CFD binding afﬁnity for variant AFD.v6, which combined VL-
Figure 1. Key contacts observed in structure of AFD:CFD complex (4D9R). AFD and CFD are shown as green and aqua ribbons, respectively. Residues in contact with (A)
CFD-Lys223 or (B) CFD-Arg172 are shown in space-ﬁlling and numbered. Figure prepared using Pymol (Schr€odinger).
Table 1. Effect of amino acid changes on afﬁnity for CFD determined using surface
plasmon resonance.
Variant Amino Acid Substitutions KD (pM)
AFD NA 10
AFD.v1 VL-D28S 10
AFD.v2 VL-D30E 10
AFD.v3 VL-D31S 10
AFD.v4 VL-D32S 26
AFD.v5 VL-D28S:D31S:D32S 280
AFD.v6 VL-D30E:D31S VH-D61E 10
AFD.v7 VL-D30E:D31S:D92E VH-D61E 10
AFD.v8 VL-D28S:D30E:D31S VH-D61E 16.7 § 4.4
AFD.v9 VL-D28S:D30E:D31S:N34S VH-D61E 30
AFD.v10 VL-D28S:D30E:D31S:D92E VH-D61E 70
AFD.v11 VL-D28S:D30E:D31S VH- N52S:D61E 70
AFD.v12 VL-D28S:D30E:D31S VH-D61E:N101D 23
AFD.v13 VL-D28S:D30E:D31S VH-D61E:N101Q 60
AFD.v14 VL-D28S:D30E:D31S VH-D61E:N101S 25.6 § 6.3
Mutants are named based on location in light chain variable domain (VL) or heavy
chain variable domain (VH): single letter code for the wild-type residue followed
by sequence position (Kabat numbering scheme) followed by single letter code
for the substituted amino acid. Multiple changes on the same domain are sepa-
rated by a colon.
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D30E, D31S, and VH-D61E, was equivalent to that for AFD.
The VH-D61E substitution eliminated an isomerization site
that is not in contact with CFD and the substitution did not
perturb CFD binding. Variant AFD.v8, which was generated by
combining substitutions VL-D28S, D30E, D31S, and VH-
D61E, had only a small (»2-fold) loss in afﬁnity for CFD. The
Asp to Ser substitutions altered the surface patch of negative
charge contributed by CDR-L1 (Figure 3B).
Solubility measurements on AFD and AFD variants
The solubility of AFD, AFD.v2, AFD.v6, and AFD.v8 at pH 6 and
under low ionic strength was compared. Solutions of AFD and
AFD.v2 (»100mg/mL in 20mMHis-HCl, pH 6) were noticeably
turbid; a large pellet formed upon centrifugation, and there was a
signiﬁcant decrease in the protein concentration in the superna-
tant (Figure 2). The solution of AFD.v6 was less turbid, with a
smaller precipitate formed upon centrifugation and a higher pro-
tein concentration in the supernatant. No precipitate was
observed for AFD.v8, with the protein concentration in the super-
natant consistent with full solubility of the Fab under these condi-
tions. Variants AFD.v6 and AFD.v8 have 1 and 2 fewer negatively
charged residues, respectively, than AFD; however, these changes
did not produce a signiﬁcant change in isoelectric point (pI).
Since long-acting delivery will involve extended exposure of
an antibody Fab to neutral pH, which favors deamidation, we
tested the effect of substituting potential sites of deamidation in
the CDRs with other residues. For Asn residues in contact with
CFD in the co-crystal structure (VL-N34, VH-N52, VH-N101;
Figure 1B) only Asn-101 showed a signiﬁcant rate of deamida-
tion under neutral pH conditions. Results of peptide mapping
showed that the extent of deamidation at Asn-101 increased by
11% for a 10-mg/mL sample of AFD.v6 when incubated in
10 mM phosphate buffer, pH 7.4 for 10 weeks at 37C. Substitu-
tion of Asn-101 with Asp or Ser resulted in small losses in afﬁnity
for CFD (Table 1). As shown in Table 2, AFD and variants AFD.
v7, AFD.v8, and AFD.v14 were equipotent with respect to
Figure 2. Solubility of AFD molecules in 20 mM His-HCl, pH 6.0. Protein concentration in supernatant following centrifugation was determined by UV absorbance meas-
urements. Photograph shows precipitate obtained upon centrifugation of the dialyzed sample.
(A)
(B)
Figure 3. Self-association and molecular charge of AFD. (A) One potential cluster
from molecular docking simulations of AFD self-association. (B) Electrostatic sur-
face modeled for AFD (left) and AFD.v8 (right). Surfaces calculated and displayed
using Pymol (Schr€odinger) and AFD coordinates from AFD:fD complex structure
(pdb code: 4D9R). AFD.v8 substitutions were modeled onto 4D9R structure.
Table 2. Potency in CFD inhibition assay.
Variant IC50 (nM) AP Hemolysis IC50 (pM) fB activation
AFD 3.4 43
AFD.v7 3.8 50
AFD.v8 4.2 45
AFD.v14 4.1 51
MABS 1299
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inhibition of CFD enzymatic activity, as determined using a
hemolysis assay and an assay of CFD-dependent factor B
activation.
As shown in Figure 2, variant AFD.v14 was less soluble than
AFD.v8 at pH 6, low ionic strength conditions. However, the
solubility of AFD.v14 increased from 47 mg/mL to 80 mg/mL
when the samples were incubated overnight at 37C prior to
centrifugation. In addition, AFD.v8 and AFD.v14 show high
solubility at physiological pH and ionic strength. At the highest
protein concentrations tested for solubility in phosphate-buff-
ered saline (PBS), clear solutions of AFD.v8 (269 mg/mL) and
AFD.v14 (372 mg/mL) were obtained. On the other hand, pre-
cipitation was observed for AFD, which had a maximum solu-
bility of 227 mg/mL in PBS.
Assessment on chemical and physical stability
of AFD variants
To further compare the suitability of variants AFD.v8 and
AFD.v14 as candidate therapeutic agents, we performed stabil-
ity studies at a concentration of 100 mg/mL Fab in PBS. The
conditions simulated those expected during extended exposure
to physiological conditions in a long-acting delivery system.
Both AFD.v8 and AFD.v14 retained antigen-binding capacity
upon incubation in PBS at 37C for at least 10 weeks (Figure 4).
The loss in binding capacity at 10 weeks as determined using
SPR was less than the standard error (§10%) in the measure-
ments. In contrast, the binding capacity of AFD decreased by
»30% at 10 weeks. Both variants showed a low tendency to
aggregate under this stress condition (Supplemental Figure 2)
and basic peak formation was absent (Supplemental Figure 3).
The rate of acidic variant generation for AFD.v14, which has
the additional VH-N101S change, was negligible, suggesting
that deamidation of VH-Asn101 accounted for the acidic spe-
cies production in AFD. AFD.v8 showed good stability in a for-
mulation with high concentration and low ionic strength, pH
5.5 (Supplemental Figures 4–5). At a concentration of 272 mg/
mL and pH 5.5, AFD.v8 retained >80% of antigen-binding
capacity after a 4-month incubation at 37C (Supplemental
Figure 4). Loss of binding observed at 8 months likely resulted
from a decrease in monomer content, deamidation of CDR-H3
Asn-101 (17%), and isomerization of CDR-H3 Glu-95 (5%)
(Supplemental Figure 5).
Pharmacokinetic studies and simulations of AFD.v8
Given the improved stability and solubility of AFD.v8, in vivo
rabbit studies were conducted with this variant. AFD and var-
iants do not bind rabbit CFD, therefore, pharmacokinetic (PK)
experiments in rabbits provide a measure of target-independent
clearance from ocular tissue. Vitreous humor concentration-time
curves obtained following intravitreal injection of 1.0 mg AFD.
v8, or a comparator dose of ranibizumab, are shown in Figure 5.
Analysis of the data using a non-compartmental approach indi-
cated that clearance of AFD.v8 and ranibizumab is comparable.
PK parameters calculated for ranibizumab are consistent with
results of earlier studies in rabbits.18 Both antibody Fabs showed
similar exposure levels in the retina. The amino acid changes in
AFD.v8, which improved solubility and stability compared to
AFD, did not have a deleterious consequence for ocular PK.
We simulated human PK upon intravitreal injection of AFD.
v8 based on the assumption that this variant would have PK
similar to lampalizumab. The previously published lampalizu-
mab population PK model12 was used with the PK parameters
estimated for lampalizumab. In Figure 6, simulated vitreous
concentrations for AFD.v8 are shown for 2 doses, a 10-mg dose
– equivalent to that used in the lampalizumab Phase 2/3 clinical
trials – and a 2.5-fold higher dose of 25 mg. The higher dose
afforded by the increased solubility of AFD.v8 results in higher
vitreous drug concentrations, and thus higher drug exposures
compared with the 10-mg dose when given at the same treat-
ment frequency. A higher dose may potentially enable less fre-
quent dosing with similar efﬁcacy outcomes. In Table 3, the
drug concentrations and exposures for 5 dose regimens are
Figure 4. Fraction of antibody Fab active for antigen binding as determined using
SPR. Protein solutions (100 mg/mL in PBS) were incubated at 37C for various times.
Figure 5. Concentration-time proﬁle observed for ranibizumab and AFD.v8 follow-
ing intravitreal injection (1.0 mg/eye) in rabbits. Concentrations in vitreous humor
and retina were determined by ELISA. Pharmacokinetic parameters derived from a
noncompartmental analysis are shown in the inset.
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compared: 10-mg dose every 4 weeks (Q4W), 10-mg dose every
6 weeks (Q6W), 25-mg dose Q4W, 25-mg dose Q6W, and
25-mg dose every 8 weeks (Q8W). The total area under the
concentration-time curve over the course of a 72-week treat-
ment period (AUC[0-72wk]) is increased for all dosing regimens
of the higher dose relative to 10 mg Q4W, including 25 mg
Q8W. None of the dosing schemes summarized in Table 3
result in accumulation of drug since the minimum drug con-
centration between doses (Cmin) does not change appreciably
with repeat dosing. Higher Cmin is observed with 25 mg Q4W
than with 10 mg Q4W, but is lower for less frequent adminis-
tration (Q6W and Q8W) of a 25-mg dose.
Discussion
Results of analysis on AFD samples exposed to vitreous humor
conditions (data not shown) suggest that this molecule has sufﬁ-
cient in vivo stability to support an increased dosing interval.
The variants described here have improved solubility that facili-
tated higher concentration formulations. The decreased solubil-
ity of AFD observed at pH 6 and low ionic strength is thought to
reﬂect weak intermolecular electrostatic interactions that drive
assembly into higher-order structures. CDR-L1 appears to form
at least a portion of an acidic patch that is involved in this elec-
trostatic interaction since Asp to Ser amino acid changes in this
region (VL-D28S, D31S) resulted in improved solubility. In
contrast to this charge-mediated interaction, hydrophobic to
hydrophilic substitutions in the variable domains of a bispeciﬁc
IgG antibody were required to improve solubility.19 The speciﬁc
distribution of charge on AFD appears to be at least as important
as total charge in determining the solubility properties of the
molecule since the replacements in CDR-L1 did not produce a
large change in pI. The small change in pI may reﬂect altered
pKa values for some of the Asp residues in CDR-L1 of AFD such
that the pKa of the remaining residues became normalized when
Asp-28 and Asp-31 were replaced with Ser. Indeed, the high
isomerization rate of Asp-30 is consistent with an atypical, high
pKa for this residue20 because the protonated side chain favors
formation of the cyclic imide that is the intermediate for isomer-
ization. Interestingly, the highly negatively charged CDR-L1 of
AFD is encoded in themouse germline gene. AFD also conserves
positively charged regions with the variable domains of the
parental murine antibody, suggesting that the solubility behavior
observed in low ionic strength conditions is not a consequence of
the grafting of mouse CDRs into a human framework.
The challenge of engineering improved solubility is shown
by the apparent lowering of solubility (pH 6.0, low ionic
strength) upon introduction of the VH-N101S substitution.
Variants AFD.v8 and AFD.v14 differ by this change, but other-
wise have the same pI and calculated net charge at pH 6.0. In
addition to forming contacts with antigen in the CFD-bound
structure of AFD, Asn-101 also appears to make hydrogen-
bonding interactions with other residues of CDR-H3. Modeling
indicates a Ser residue could not make equivalent interactions,
suggesting that the conformation of CDR-H3 is de-stabilized in
AFD.v14, which has consequences for solubility at pH 6.0 and
low ionic strength. Therefore, in choosing a candidate for long-
acting delivery, the incremental increase in chemical stability
for AFD.v14 compared to AFD.v8 must be balanced by a con-
sideration of their solubility differences, and the slightly weaker
(<2-fold) afﬁnity of AFD.v14 for CFD.
The stability of both AFD.v8 and AFD.v14, as indicated by
the full retention of antigen-binding capacity for at least 10
weeks in 37C PBS, renders both suitable for long-acting deliv-
ery to the eye (Figure 4). Charge variant generation was negligi-
ble for AFD.v14, whereas an appreciable rate of acidic species
production, likely attributed to VH-N101 deamidation, was
observed for AFD.v8. The additional beneﬁt of the VH-N101S
substitution to preservation of antigen-binding was not realized
in this experiment. This is not surprising because, although the
acidic peak accumulated to » 25% under these stress condi-
tions, the effect of a negatively charged residue at this position
(Asp in AFD.v12) on binding afﬁnity was small (<2-fold). A
comparison of all variants suggests that amino acid changes
VL-D28S and D30E improve retention of antigen-binding
capacity for thermally stressed samples.
AFD.v8 is well adapted for high concentration (250 mg/
mL) formulations as it showed low viscosity (Supplemental
Figure 6) that facilitates intravitreal injection. Either a high
concentration formulation, and hence higher dose, or a slow
release formulation providing sustained exposure could enable
an additional therapeutic option with less-frequent dosing for
patients. Efﬁcacy of AFD.v8 may be driven by total drug expo-
sure, maintenance of drug concentrations above an efﬁcacy
threshold, or other PK characteristics. If total drug exposure
Table 3. Simulated human vitreous exposure levels and concentrations.
Dose scheme AUC[0-72wk] (mg/mL
day) Relative AUC Cmin (mg/mL)
10 mg Q4W 440 1 77
10 mg Q6W 293 0.67 11
25 mg Q4W 1142 2.5 207
25 mg Q6W 762 1.67 31
25 mg Q8W 572 1.25 5
Figure 6. Simulated human vitreous concentration-time proﬁles for 10- and 25-mg
doses. Simulations are based on the previously published population pharmacoki-
netic model for lampalizumab.12 The 10-mg and 25-mg dose lines represent pre-
dictions for a typical patient.
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drives efﬁcacy, the 25-mg dose would be expected to have
human vitreal exposure (Table 3) superior to the 10-mg Q4W
dose over the course of treatment whether given Q4W, Q6W,
or Q8W; however, the 10-mg Q4W dose would produce higher
Cmin than 25-mg Q6W or Q8W and may be superior if mainte-
nance of drug concentrations above an efﬁcacy threshold is
needed for efﬁcacy and that threshold is passed with less fre-
quent dosing. Further clariﬁcation of the relationship between
PK and efﬁcacy awaits the outcome of the pivotal trials of
lampalizumab in GA. Nonetheless, a higher dose formulation
has potential to bring further beneﬁt to patients.
A relatively stable, highly concentrated (272 mg/mL) formula-
tion with low ionic strength, pH 5.5, is achievable for AFD.v8,
whereas the parental antibody, AFD, showed low solubility under
this condition. Full antigen binding was maintained for at least 2
months at 37C (Supplemental Figure 4), suggesting that a high
concentration liquid formulation of AFD.v8 stored frozen or at 2–
8C is viable. However, elimination of the primary degradation
mode of AFD, VL-Asp-30 isomerization, has revealed other,
slower degradation processes, including isomerization of a gluta-
mic acid residue. AFD has a short CDR-H3: 95E-G-G-V-N-N102
(Kabat numbering). Since Glu-95 forms a key contact with CFD,8
isomerization of this residue, albeit at a very slow rate, could affect
binding. Further engineeringmay be required to obtain amolecule
with retention of full activity for4months upon thermal stress.
Therapeutic agents administered to the eye via intravitreal
injection must be isotonic in order to minimize intraocular
pressure changes and the potential for retinal edema and
detachment.10 They should also be low in viscosity for ease of
administration. Although increased salt concentration can pre-
vent the electrostatic-mediated association we have described
here for AFD, increased salt poses challenges to maintain the
tonicity of the formulation. The alternative approach we have
demonstrated is to mitigate the self-association through struc-
ture-based design of sequence variants with improved proper-
ties. This approach could be applied to other therapeutic
antibodies that have similar limitations in solubility and stabil-
ity, provided that sufﬁcient information is available to design
agents that retain potency and favorable PK properties. An
anti–interleukin (IL)13 antibody was shown to have an aggre-
gation-prone sequence in CDR-H3, but amino acid changes to
improve solubility resulted in decreased IL13 binding,
increased viscosity or tendency to aggregate.21,22 The most suc-
cessful approach to increase solubility of the anti–IL13 anti-
body was to introduce a glycosylation site that could mask the
aggregation-prone region with minimal effect on IL13 binding.
Addition of a glycosylation site is not an option for production
in Escherichia coli, which is used for ranibizumab and lampali-
zumab. Since we introduced amino acid changes only in the
hypervariable regions of the antibody Fab, we expect these var-
iants to have low risk for increased immunogenicity in humans.
Materials & methods
Materials
Puriﬁed human VEGF (1-165), human factor D (CFD), ranibi-
zumab, and AFD were supplied by Genentech, Inc.
Methods
Mutant construction and Fab expression/puriﬁcation
Mutations were introduced by site-directed mutagenesis using
the QuikChangeII site-directed mutagenesis kit (Agilent) fol-
lowing the manufacturer’s instructions. Oligonucleotide pri-
mers specifying the required codon changes were synthesized
by the Genentech oligonucleotide synthesis lab. Plasmids with
designed changes were identiﬁed and conﬁrmed by DNA
sequencing at Genentech. For small scale-expression and puri-
ﬁcation, DNA was transformed into Escherichia coli strain
64B4, and the cells were grown overnight in low phosphate-
containing media. The Fab was puriﬁed from cell lysates pre-
pared using PopCulture extraction buffer (EMD Millipore)
through chromatography on Protein G GraviTrap (GE Health-
care). For larger scale puriﬁcation, cell paste from 10 L fermen-
tation of the transformed cells was provided by the Genentech
fermentation group. Cell paste was suspended in extraction
buffer and homogenized using a microﬂuidizer. Fabs were cap-
tured by immunoafﬁnity chromatography on Protein G-
Sepharose and eluted with a low pH buffer. The low pH eluate
was adjusted to pH 5.0 and further puriﬁed by cation exchange
chromatography on an S-Sepharose column. Identities of the
puriﬁed proteins were conﬁrmed by mass spectroscopy and the
pooled fractions were concentrated to » 10 mg/mL, and
exchanged into PBS buffer via diaﬁltration.
Binding afﬁnity by surface plasmon resonance
measurements
Determination of the KD for CFD binding to immobilized AFD
was determined by SPR measurements on a Biacore T200
instrument using a protocol similar to that described by Ultsch
et al.23 except that antibody Fabs were immobilized on a Series
S CM5 sensor chip using the anti-huFab capture kit (GE
healthcare Cat. # 28-9583-25) following the manufacturer’s
protocol. The running buffer was 10 mM HEPES pH 7.4,
150 mM NaCl, 0.01% PS20, the temperature of analysis was
25C, and a ﬂow rate of 30 mL/min was used.
Alternative pathway hemolysis and factor B TR-FRET assays
Half-maximal inhibition (IC50) values for inhibition of com-
plement activation in an alternative pathway hemolysis assay
were determined as described previously.24
Factor B TR-FRET assay – Dilutions of AFD Fab or control
were prepared in enzymatic reaction buffer (ERB; 75 mM
NaCl, 1 mM MgCl2, 25 mM Tris, 0.005% polysorbate 20, pH
7.3) at a 4x concentration and combined in equal volumes with
0.5 nM CFD (Complement Technology) or ERB (no enzyme
control). The CFD/AFD mixtures (7 ml/well) were added to
364-well Proxiplate F plus black plates (Perkin Elmer Health
Sciences) followed by 7 ml/well of substrate. The substrate con-
sisted of a mixture of C3b (Complement Technology) at 7 mg/
mL (39.7 nM) and factor B (Complement Technology) at 1 mg/
mL (10.8 nM). The Fab, enzyme, cofactor, and substrate were
incubated for 45 min at room temperature with gentle agita-
tion. The reaction was stopped with 7 mL/well of a detection
reagent cocktail mixture consisting of 8 nM biotinylated anti–
factor Bb (2F12, GNE PRO282909), 4 nM Europium-conju-
gated anti–factor Ba (custom conjugation of 1C3, GNE
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PRO282908 by Life Technologies), and 25 nM streptavidin-
Alexa 647. The plate was incubated at room temperature in the
dark for 30 min. Time-resolved ﬂuorescence energy transfer
was detected with a PHERAstar FS microplate reader (BMG
LabTech) by exciting at 337 nm and detecting Europium emis-
sion at 620 nm and Alexa ﬂuor emission at 665 nm. The AFD
concentrations causing IC50 were determined by nonlinear
regression analysis using a four-parameter ﬁt model (Kaleida-
Graph Synergy Software).
Solubility testing
Protein solutions formulated in 20 mM His-HCl, pH 5.0 were
concentrated to 100 mg/mL using Amicon Centriprep YM-10
centrifugal ﬁlter units. Samples (0.5–1 mL) were placed in
Slide-A-Lyzer cassettes with a molecular weight cutoff of 10 K
(Pierce, Thermo Scientiﬁc) and dialyzed overnight at 4C ver-
sus 1 L of 20 mM His buffer, pH 6.0. Samples were removed
from the cassette, visually inspected for aggregates, centrifuged
at 14,000 x g for 10 min to pellet any insoluble material,
and the protein concentration in the supernatant was deter-
mined by UV absorbance measurements. A similar procedure
was used for comparing solubility of variants under conditions
of physiological pH and ionic strength except that the samples
were concentrated to >200 mg/mL and dialyzed overnight at
4C versus PBS.
Simulations on AFD self-association
Macromolecular docking was performed using HADDOCK 27
with restraints introduced between lysine and aspartate/gluta-
mate residues derived from antibody crosslinking data (Li Yi,
unpublished results). AFD docking utilized 279 restraints, while
control antibody (ranibizumab) docking utilized 25 restraints.
A total of 2000 rigid body trials were performed with each anti-
body complex, randomly excluding 50% of the restraints in
each trial. Semi-ﬂexible reﬁnement was performed on the top
200 decoys for each complex and reﬁned structures were clus-
tered based on root mean square deviation. The top-scoring
AFD cluster exhibited good convergence (59 decoys, rmsd 0.77
§ 0.49 A ).
Stability samples
Proteins were concentrated to » 10 mg/mL or 100 mg/mL
using centrifugal ﬁlter units as described above. Samples were
dialyzed against the buffer condition for test, PBSTN (10 mM
sodium phosphate, 137 mM NaCl, pH 7.4 containing 0.02%
polysorbate 20 and 0.02% sodium azide) or 10 mM His-HCl
pH 5.5, or 20 mM His-HCl pH 5.5, and then adjusted to the
ﬁnal protein concentration by further centrifugal concentration
or by dilution. Samples were incubated at 37C. Aliquots were
removed at various time points, diluted to 1 mg/mL with
10 mM His-HCl pH 5.5 10% trehalose, and snap frozen for
storage at ¡80C. CFD binding was determined as described
below. Analysis for charge variation and monomer content is
described in Supplemental Methods.
Binding capacity by SPR measurements
Functional activity for binding to immobilized CFD was
assessed by SPR measurements on a Biacore T200 instru-
ment1 (GE Healthcare) with CFD covalently immobilized on a
Series S, CM5 sensor chip using amine-coupling chemistry.
Antigen-binding active concentrations of AFD were deter-
mined using the calibration-dependent concentration analysis
routine of the Biacore T200 evaluation software. A calibration
curve of unstressed AFD, as well as samples of stressed mate-
rial, were prepared through gravimetric dilution. All samples
(200 mL volume) were prepared using 1X running buffer
(10 mM HEPES pH 7.4, 150 mM NaCl, 0.01% PS20); 60-mL
aliquots were injected over the speciﬁc antigen surface using a
ﬂow rate of 10 mL/min, and bound antibody Fab was deter-
mined from the SPR signal near the end of the sample injection.
The sensor chip surface was regenerated between binding cycles
through injection of 10 mM Gly-HCl, pH 2.1. The standard
curve of starting material was used to determine the relation-
ship of SPR signal to antibody concentration using a four-
parameter function to analyze the data. Parameters calculated
from the standard curve were used to calculate the antigen-
binding concentration of test samples based on the observed
SPR signal. The ratio of this concentration to the protein con-
centration determined by absorbance measurements gives the
fraction or percent binding. This method was qualiﬁed with
§10% standard error using a recovery experiment.
ELISA assay of pharmacokinetic study samples
Analyses of AFD.v8 and ranibizumab were done using a
generic immunoglobulin PK ELISA25 as previously described
with the following modiﬁcations. 384-well ELISA plates were
blocked with PBS plus 0.5% bovine serum albumin (BSA) at
room temperature. The samples, controls, and standard curves
were prepared in sample assay diluent at pH 7.4; rabbit vitreous
humor or retinal homogenate samples were diluted at a mini-
mum of 1:100 or 1:50, respectively. Detection was with 83.3 ng/
mL HRP-conjugated sheep anti–human IgG mAb (Bethyl Lab-
oratories Inc) in conjugate assay diluent (PBS C 0.5% BSA C
0.05% Tween 20 C 10 ppm Proclin), followed by tetramethyl
benzidine peroxidase substrate (Moss, Inc.,). Assay sensitivities
in rabbit vitreous or retinal homogenate were 62.5 ng/mL or 31
ng/mL, respectively.
Pharmacokinetic experiments and assay
Animal studies were conducted at Covance Laboratories
(Madison, WI) in accordance with the Animal Welfare Act,
the Guide for the Care and Use of Laboratory Animals, and
the Ofﬁce of Laboratory Animal Welfare.
Na€ıve New Zealand white rabbits (n D 24; male; >2.5 kg;
aged 5–7 months at the time of dosing) were treated with AFD.
v8 or ranibizumab via a single bilateral intravitreal injection
and observed for up to 27 days.
Fabs were administered by a single 50-mL intravitreal injec-
tion (1.0-mg dose) to both eyes in all animals under sedation.
Doses were administered by a board-certiﬁed veterinary oph-
thalmologist in accordance with Covance standard operating
procedures (SOP).
All animals were euthanized in accordance with Covance
SOP. At the time of euthanasia, both eyes were enucleated.
Aqueous humor was collected fresh and then each eye was ﬂash
frozen in liquid nitrogen and stored at approximately ¡70C.
Within 2 days, the frozen vitreous and retina tissues were
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collected separately as right and left eye. All tissues were kept at
¡70C until analysis using the ELISA described above.
The following PK parameters were determined by noncom-
partmental analysis using the nominal time and dose (Phoenix
WinNonlin, Pharsight Corp): Cmax (maximum observed con-
centration); AUCall (area under the vitreous concentration ver-
sus time curve from time 0 to Clast); CL (clearance calculated as
nominal dose (mg/kg)/AUCinf); t1/2, elim (half-life associated
with the terminal phase [ln(2)λz]) and Vss (volume of distribu-
tion at steady-state).
Pharmacokinetic simulations
PK simulations were generated based on the previously pub-
lished lampalizumab population PK model.12 The PK parame-
ters used in simulations are those parameters estimated for
lampalizumab in the ocular-serum target-mediated drug dispo-
sition model for a typical patient.
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